1. Home
  2. MUR vs ADMA Comparison

MUR vs ADMA Comparison

Compare MUR & ADMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Murphy Oil Corporation

MUR

Murphy Oil Corporation

HOLD

Current Price

$31.45

Market Cap

4.4B

Sector

Energy

ML Signal

HOLD

Logo ADMA Biologics Inc

ADMA

ADMA Biologics Inc

HOLD

Current Price

$16.29

Market Cap

4.7B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MUR
ADMA
Founded
1950
2004
Country
United States
United States
Employees
N/A
N/A
Industry
Oil & Gas Production
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Energy
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
4.4B
4.7B
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
MUR
ADMA
Price
$31.45
$16.29
Analyst Decision
Hold
Strong Buy
Analyst Count
16
2
Target Price
$29.36
$28.50
AVG Volume (30 Days)
2.5M
2.3M
Earning Date
01-28-2026
03-02-2026
Dividend Yield
4.09%
N/A
EPS Growth
N/A
205.35
EPS
0.99
0.86
Revenue
$2,746,335,000.00
$488,559,000.00
Revenue This Year
N/A
$22.13
Revenue Next Year
N/A
$24.15
P/E Ratio
$32.08
$19.37
Revenue Growth
N/A
27.63
52 Week Low
$18.95
$13.50
52 Week High
$35.19
$25.67

Technical Indicators

Market Signals
Indicator
MUR
ADMA
Relative Strength Index (RSI) 47.79 33.46
Support Level $30.19 $16.62
Resistance Level $32.39 $17.79
Average True Range (ATR) 1.35 0.77
MACD -0.16 -0.16
Stochastic Oscillator 26.72 7.54

Price Performance

Historical Comparison
MUR
ADMA

About MUR Murphy Oil Corporation

Murphy Oil Corp is an oil and gas exploration and production company, with both onshore and offshore operations and properties. It operates in two geographic reportable segments the United States and Canada. It generates the majority of its revenue form the United States.

About ADMA ADMA Biologics Inc

ADMA Biologics Inc is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The segments of the company are ADMA BioManufacturing which generates maximum revenue and Plasma Collection Centres, and corporate segment. The company sells plasma-derived intermediate fractions to certain customers, which are generated as part of its FDA-approved manufacturing process for IG and IVIG products. It also provides laboratory contracting services to certain customers and anticipates providing contract filling, labeling and packing services. The company derives maximum revenue from United States.

Share on Social Networks: